Clinical Trials Directory

Trials / Completed

CompletedNCT00974896

QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors

A Phase 1b Study of AMG 479 With Biologics or Chemotherapy in Adult Subjects With Advanced Solid Tumors

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
46 (actual)
Sponsor
NantCell, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in combination with bevacizumab, sorafenib, panitumumab, erlotinib, or gemcitabine in subjects with advanced solid tumors. Up to 126 subjects may be enrolled. Sorafenib and erlotinib combo cohorts are enrolling. All other combo cohorts are closed to enrollment.

Conditions

Interventions

TypeNameDescription
DRUGAMG 479AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).

Timeline

Start date
2006-12-01
Primary completion
2010-09-01
Completion
2011-04-01
First posted
2009-09-11
Last updated
2016-10-27

Source: ClinicalTrials.gov record NCT00974896. Inclusion in this directory is not an endorsement.